Ligand id: 9802

Name: CFZ533

Immunopharmacology Comments
CFZ533 is an anti-CD40 mAb that is being evaluated in clinical trials as a therapy for some autoimmune conditions and for preventing/reducing solid organ transplant rejection. It blocks CD40-CD40L signalling capacity [1].
Immunopharmacology Disease
Disease X-Refs Comment References
Graves' disease Disease Ontology: DOID:12361
Phase 2 clinical candidate for Graves' disease- see NCT02713256
Myasthenia gravis Disease Ontology: DOID:437
OMIM: 254200
Orphanet: ORPHA589
Phase 2 clinical candidate for moderate to severe Myasthenia gravis- see NCT02565576
Sjögren's syndrome Orphanet: ORPHA378
Phase 2 clinical candidate for primary Sjögren's syndrome- see NCT02291029
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Phase 1 clinical candidate for RA- see completed trial NCT02089087